Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab183319-100μg
|
100μg |
10
|
$189.90
|
|
|
Ab183319-1mg
|
1mg |
4
|
$919.90
|
|
|
Ab183319-5mg
|
5mg |
1
|
$2,299.90
|
|
|
Ab183319-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$3,679.90
|
|
Purity>90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAE)
| Product Name | Farletuzumab-MMAE (anti-FOLR1) - Primary antibody, specific to FOLR1, >90% (SDS-PAGE&SEC), high purity, Human IgG1 |
|---|---|
| Synonyms | adult antibody | Adult folate binding protein antibody | Adult folate-binding protein antibody | FBP antibody | Folate Binding Protein antibody | Folate Receptor 1 Adult antibody | Folate receptor 1 antibody | Folate Receptor 1 Precursor antibody | Folate |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | FOLR1 |
| Conjugation | MC-VC-PAB-MMAE |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Farletuzumab-MMAE (anti-FOLR1) is an antibody-drug conjugate (ADC) composed of humanized anti-human folate receptor-alpha (FRα) and the cytotoxic agent monomethyl auristatin (MMAE) via a MC-Vc linker. It has a potent antitumor activity. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145 kDa |
| Purification Method | Protein A purified |
| Purity | >90% (SDS-PAGE&SEC) |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Farletuzumab-MMAE (anti-FOLR1) (Ab183319) - Flow Cytometry
Flow Cytometry analysis of Hela cells labelling FOLR1 (red) with Farletuzumab-MMAE (anti-FOLR1) (Ab183319). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Farletuzumab-MMAE (anti-FOLR1) (Ab183319) - Flow Cytometry
Flow Cytometry analysis of MCF-7 cells labelling FOLR1 (red) with Farletuzumab-MMAE (anti-FOLR1) (Ab183319). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Farletuzumab-MMAE (anti-FOLR1) (Ab183319) - SEC
The purity of Farletuzumab-MMAE (anti-FOLR1) (Ab183319) is more than 95% verified by HPLC.
Farletuzumab-MMAE (anti-FOLR1) (Ab183319) - ELISA
Immobilized Recombinant Human FOLR1 protein (rp167844) at 1.0 μg/mL can bind Farletuzumab-MMAE (anti-FOLR1) (Ab183319) with the EC₅₀ of 36.63 ng/mL.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jun 21, 2024 | Ab183319 | |
| Certificate of Analysis | Jun 21, 2024 | Ab183319 | |
| Certificate of Analysis | Jun 21, 2024 | Ab183319 |